LegalApr 9, 2026, 04:32 PM
Apimeds Pharmaceuticals Declares Majority Stockholder Actions to Remove Directors and Officers Null and Void
AI Summary
Apimeds Pharmaceuticals US, Inc. (APUS) announced that actions previously taken by majority stockholders, Inscobee Inc. and Apimeds, Inc. (Apimeds Korea), to remove four directors and two executive officers are null and void. The company stated that these purported removals, including those of CEO Dr. Vin Menon and CFO Erick Frim, violated binding contractual obligations under a Support Agreement and applicable Delaware law. This declaration highlights an ongoing corporate governance dispute following a Merger Agreement signed in December 2025, signaling potential instability or further legal challenges regarding company leadership.
Key Highlights
- Apimeds Pharmaceuticals US, Inc. declared the March 20, 2026, actions by majority stockholders Inscobee Inc. and Apimeds, Inc. (Apimeds Korea) to be null and void.
- The nullified actions included the purported removal of four directors: Elona Kogan, Jakap Koo, Carol O’Donnell, and Dr. Bennett Weintraub.
- The purported removal of Chief Executive Officer Dr. Vin Menon and Chief Financial Officer Erick Frim was also declared null and void.
- The company stated these actions, including the appointment of replacement directors, were in direct violation of binding contractual obligations under a Support Agreement and applicable Delaware law.
- The dispute arises in the context of a Merger Agreement signed and closed on December 1, 2025.
Price Impact
More from APUS